AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 251 min read$STEM

UBS Upgrades Stem to Buy From Neutral, Price Target is $7

UBS upgraded Stem Inc. to Buy from Neutral, setting a price target of $7. The stock has a 5-day change of +2.09% and a year-to-date change of -17.37%. Previously, UBS had a Neutral rating with a $10.50 target.

Original reporting
marketscreener.com
Published Sep 25, 2026, 11:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$STEM
Bearish
medium confidence
Mentioned
$STEM
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$STEMBearishMed
01

Why it matters

The downgrade suggests weaker near‑term growth expectations, likely prompting short‑term selling pressure.

02

Market read

Analyst upgrade with a lower price target can move the stock and influence sector sentiment.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the downgrade.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Stem, Inc. is a biotech company focused on energy storage solutions. UBS analysts revised their outlook based on recent performance and outlook.

Company-level read

Ticker impact

$STEMBearishMedium confidence
Context

UBS upgraded Stem to Buy and cut the price target to $7 from $10.50.

Expected impact

Potential downside of 5-10% as investors adjust expectations.

Evidence & confidence

UBS downgrade reflects weaker outlook; price target cut signals reduced valuation.

Market effects

Sector

May weigh on other biotech stocks as analysts reassess valuations.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Some investors may see the lower target as a buying opportunity if they believe the market overreacted.

Key entities

  • Company
    Stem, Inc.

    Biotech firm providing energy storage solutions.

  • Analyst
    UBS

    Investment bank that issued the upgrade and new price target.

Read at source← All news

Related articles

AUG 12
$STEMMed

Stem, Inc.: Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary

Stem, Inc. (NYSE: STEM) said Solarmarkt Group, with EPC partner Pannonwatt, selected Stem’s PowerTrack Energy Management System to hybridize two operating utility-scale solar plants in Hungary. The five-year agreement covers adding 40 MW/80 MWh batteries to each site, targeting commercial operation by Sept 2026 and participation in Hungary’s aFRR market.

finanznachrichten.de3 min
AUG 12
$STEMMed

STEM, INC. (STEM): Completion of Acquisition or Disposition of Assets

STEM, INC. (STEM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99 Stem Announces Second Quarter 2026 Results Achieved fifth consecutive quarter of positive adjusted EBITDA PowerTrack TM software revenue up 11% YoY PowerTrack TM Energy Management System (EMS) recognized as leading, global innovative solution with The smarter E AWARD w

SEC EDGAR 8-K6 min
JUL 28
$PSKYMed

Why Did PSKY, UBER, STEM Stocks Plummet To 52-Week Lows?

Stocks of Paramount Skydance (PSKY), Uber (UBER) and Stem (STEM) hit 52-week lows. PSKY fell after delaying its Warner Bros. Discovery merger to June 1, 2027 amid a multistate antitrust suit. UBER dropped on slower growth and Waymo partnership concerns. STEM slid on EV charging weakness and Barclays cut its price target to $8; revenue fell 11% to $29M.

stocktwits.com4 min